Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425267 | 0.87 | KMT2A (0.47) | MAPK1KMT2AMEN1POLBCYP1A2 | |
| SCHEMBL20333225 | 0.85 | MAPK1 (0.56) | MAPK1KMT2AMEN1POLBCYP1A2 | |
| SCHEMBL14921134 | 0.85 | MAPK1 (0.51) | MAPK1KMT2AMEN1POLBCYP1A2 | |
| SCHEMBL20333222 | 0.85 | KMT2A (0.45) | MAPK1KMT2AMEN1POLBLMNA | |
| SCHEMBL4552882 | 0.84 | MAPK1 (0.45) | MAPK1KMT2AMEN1POLBCYP1A2 | |
| SCHEMBL16711862 | 0.82 | KMT2A (0.47) | MAPK1KMT2AMEN1POLBLMNA | |
| SCHEMBL6026553 | 0.82 | MAPK1 (0.55) | MAPK1KMT2AMEN1POLBCYP1A2 | |
| SCHEMBL784072 | 0.80 | LMNA (0.45) | MAPK1KMT2AMEN1POLBCYP1A2 | |
| SCHEMBL16240114 | 0.80 | KMT2A (0.53) | MAPK1KMT2AMEN1POLBLMNA | |
| SCHEMBL5200375 | 0.78 | GLA (0.53) | KMT2AMEN1POLBCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694648-B1 | 2-PYRIDINYLETHYLBENZAMIDE DERIVATIVES | BAYER SAS (FR) | 2015-07-29 | — | — | EP | disclosed |
| US-7560567-B2 | 2-pyridinylethylbenzamide derivatives | BAYER CROPSCIENCE S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-20070099965-A1 | 2-Pyridinylethylbenzamide derivatives | BAYER SAS (FR) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099965-A1 | 2-Pyridinylethylbenzamide derivatives | CYP1A2, CYP4B1, CYP4F2 | MAPK1 3077/4885KMT2A 1093/4885MEN1 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.